CA 19-9: A Novel Role in the Prognosis of Pancreatic Neuroendocrine Tumors

#1233

Introduction: Prognostication is difficult for neuroendocrine tumours given their long survival. Staging, grading using Ki67 and receptor status are tools commonly used, but are not without their limitations. CA 19-9 is a tumour marker used in the diagnosis and follow-up of pancreatic adenocarcinomas despite multiple confounding factors, including jaundice. CA 19-9 is not useful in the diagnosis of PNETs having a sensitivity of only 19%, but it is not known whether it has other roles in PNETs.

Aim(s): To investigate the role of CA 19-9 in prognostication for PNETs

Materials and methods: 103 PNET patients with serum CA 19-9 measured at diagnosis were studied. Histology was reviewed to confirm diagnosis and 3 cases of tumours with adenocarcinomatous features were excluded. Clinical notes were studied to identify jaundice, pancreatitis, cirrhosis and other parameters.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author:

Authors: Mills L, Ramage J, Quaglia A, Basuroy R, Srirajaskanthan R,

Keywords: CA 19-9,